{
    "clinical_study": {
        "@rank": "43564", 
        "arm_group": [
            {
                "arm_group_label": "Human Papillomavirus vaccine", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive the experimental quadrivalent Human Papillomavirus vaccine at entry, week 4 and week 26."
            }, 
            {
                "arm_group_label": "Saline placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The participants receive saline placebo at entry, week 4 and week 26."
            }
        ], 
        "brief_summary": {
            "textblock": "Cervical cancer occurs commonly in HIV-infected women in South Africa.  These women have\n      poor response to treatment of cervical cancer precursors.  This study will test whether\n      giving the quadrivalent vaccine to women prior to surgical treatment of the cervical cancer\n      precursor will improve outcomes. We hypothesize that pre-treatment HPV vaccine will result\n      in a reduced occurrence or cervical cancer precursors in follow-up."
        }, 
        "brief_title": "Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cervical High Grade Squamous Intraepithelial Lesion", 
        "condition_browse": {
            "mesh_term": "Uterine Cervical Dysplasia"
        }, 
        "detailed_description": {
            "textblock": "This is a single-center, randomized, double-blinded, placebo-controlled, phase II trial of\n      the quadrivalent human papillomavirus vaccine (qHPV) in HIV-infected women to prevent\n      occurrence of cervical HSIL after LEEP/LLETZ. Participants will undergo colposcopy with\n      directed biopsies, cervical cytology, and stored HPV testing prior to vaccination.\n      Participants will be randomized to the quadrivalent vaccine or saline placebo to be given at\n      entry, week 4, and week 26. Women will have LEEP treatment at week 4.  Participants will be\n      seen in follow-up for cervical cytology, colposcopy with directed biopsies at weeks 26 and\n      52, and stored HPV specimens. Treatment assignment will be unblinded after study follow-up\n      is completed for the last study participant.  Women aged 45 or less randomized to placebo\n      will be offered open label HPV vaccine after the study is concluded.."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. HIV infection\n\n          2. Women aged \u2265 18 years.\n\n          3. Cervical HSIL on biopsy (i.e. CIN2 and/or CIN3)\n\n          4. For participants of reproductive potential, negative serum or urine pregnancy test\n\n          5. All study participants must agree not to participate in a conception process (e.g.,\n             active attempt to become pregnant or in vitro fertilization) during study\n             participation (from the time of study entry until week 52).\n\n        Exclusion Criteria:\n\n          1. History or current biopsy diagnosis of invasive or microinvasive cervical, vaginal,\n             vulvar, anal or oropharyngeal cancer\n\n          2. Prior hysterectomy\n\n          3. Cervical cryotherapy or LEEP/LEETZ within one year of entry.\n\n          4. Cervical, vulvar, or vaginal lesions suspicious for cancer, unless biopsies show no\n             invasive cancer\n\n          5. Prior receipt of one or more doses of an HPV vaccine.\n\n          6. Receipt of anticoagulants other than aspirin or nonsteroidal anti-inflammatory drugs\n             (NSAIDS) within 14 days prior to entry.\n\n          7. Known allergy/sensitivity or any hypersensitivity to yeast or any of the components\n             of the study product or its formulation (see section 5.2 for a list of components).\n\n          8. Hemophilia or other bleeding diatheses.\n\n          9. Use of any systemic antineoplastic or immunomodulatory treatment, systemic\n             corticosteroids, other than inhaled corticosteroids or prednisone  \u2264 10 mg (or\n             equivalent) , investigational vaccines, interleukins, interferons, growth factors, or\n             intravenous immunoglobulin (IVIG) within 45 days prior to study entry.\n\n         10. Breastfeeding\n\n         11. Less than 3 months post-partum"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01928225", 
            "org_study_id": "QHPV-RTC"
        }, 
        "intervention": {
            "arm_group_label": [
                "Human Papillomavirus vaccine", 
                "Saline placebo"
            ], 
            "description": "The participants receive the qHPV vaccine at entry, week 4 and week 26", 
            "intervention_name": "Human Papillomavirus vaccine", 
            "intervention_type": "Biological", 
            "other_name": "qHPV vaccine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HSIL", 
            "CIN", 
            "HPV", 
            "HPV vaccination", 
            "gardasil", 
            "HIV", 
            "cervical dysplasia", 
            "LEEP", 
            "cervical cancer"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "location": {
            "contact": {
                "email": "cindy.firnhaber@righttocare.org", 
                "last_name": "Cynthia Firnhaber, M.D", 
                "phone": "+27 11 2768860"
            }, 
            "contact_backup": {
                "email": "idejong@witshealth.co.za", 
                "last_name": "Ina De Jongh", 
                "phone": "+27 11 2768800"
            }, 
            "facility": {
                "address": {
                    "city": "Johannesburg", 
                    "country": "South Africa", 
                    "state": "Gauteng", 
                    "zip": "2092"
                }, 
                "name": "Clinical HIV Research Unit"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Placebo-controlled Trial of Pre-treatment HPV Vaccination on Outcomes to LEEP Treatment of Cervical High Grade Squamous Intraepithelial Lesions in HIV-infected Women.", 
        "overall_official": [
            {
                "affiliation": "Weill Medical College of Cornell University", 
                "last_name": "Timothy J Wilkin, M.D. MPH", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University or Witswatersrand", 
                "last_name": "Cynthia Firnhaber, M.D.", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Africa: Medicines Control Council", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "HSIL on cervical cytology or HSIL on cervical biopsy", 
            "measure": "Cervical HSIL", 
            "safety_issue": "No", 
            "time_frame": "up to 52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01928225"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Witwatersrand, South Africa", 
            "investigator_full_name": "Cynthia S Firnhaber", 
            "investigator_title": "Technical Director of the Clinical HIV Research Unit", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Cervical cytology abnormalities according to the Bethesda scale.", 
                "measure": "Cervical Cytology", 
                "safety_issue": "No", 
                "time_frame": "Week 26 and Week 52"
            }, 
            {
                "description": "Proportion of participants with stored cervical swabs for future HPV DNA testing at these time points.", 
                "measure": "Stored cervical swabs", 
                "safety_issue": "No", 
                "time_frame": "Week 0, 4, 26 and 52"
            }, 
            {
                "description": "We will report the proportion of participants with stored cervical fluid, plasma, serum, PBMC, and whole blood lysate at these time points.", 
                "measure": "Stored specimens from immunology subset participants", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, 4, 26 and 52"
            }, 
            {
                "description": "Cervical HSIL at week 26 and 52 in women stratified by whether cervical HSIL is found on LEEP/LLETZ biopsy, and stratified by whether LEEP/LLETZ margins have HSIL detected.", 
                "measure": "Subgroup analyses of primary outcome", 
                "safety_issue": "No", 
                "time_frame": "Weeks 26 and 52"
            }
        ], 
        "source": "University of Witwatersrand, South Africa", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Witwatersrand, South Africa", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}